ÃÀÍÐÂå¶ûÓëËûÍ¡ÀàÒ©ÁªºÏÖÎÁÆÐļ¡¹£ËÀµÄÁÙ´²ÁÆЧ
ÕªÒª£ºÄ¿µÄ£ºÌ½ÌÖ¶ÔÐļ¡¹£ËÀ»¼Õß²ÉÈ¡ÃÀÍÐÂå¶û+ËûÍ¡ÀàÒ©Îï½øÐÐÁªºÏÖÎÁƵÄÁÙ´²Ð§¹û¡£·½·¨£º³éÈ¡ÓÚ2017Äê2ÔÂ~2018Äê2ÔÂÊÕÖεÄ112ÀýÐļ¡¹£ËÀ»¼Õß½øÐжԱÈÑо¿£¬¸ù¾ÝÓÃÒ©·½Ê½²»Í¬½«Æä·ÖΪµ¥Ò»×éºÍÁªºÏ×飬¸÷×é·Ö±ðΪ56Àý»¼Õß¡£µ¥Ò»×é½ö²ÉÈ¡³£¹æÖÎÁƵķ½Ê½£¬ÁªºÏ×éÔò²ÉÈ¡ÃÀÍÐÂå¶û+ËûÍ¡ÀàÒ©ÎïµÄÁªºÏÖÎÁÆ£¬¹Û²ì²¢¶Ô±Èµ¥Ò»×éºÍÁªºÏ×éµÄÖÎÁÆЧ¹ûÒÔ¼°¸÷ÏîÆäËûÖ¸±ê¡£½á¹û£ºÁªºÏ×éµÄÖÎÁÆÓÐЧÂÊÒÔ¼°¸÷ÏîÁÙ´²Ö¸±êµÈ¾ùÓÅÓÚµ¥Ò»×飬P£¼0.05±íʾ²îÒìÓÐͳ¼ÆѧÒâÒå¡£½áÂÛ£º¶ÔÐļ¡¹£ËÀ»¼Õß²ÉÈ¡ÃÀÍÐÂå¶û+ËûÍ¡ÀàÒ©Îï½øÐÐÁªºÏÖÎÁÆ£¬ÖÎÁÆЧ¹û¿Ï¶¨¡£ ¹Ø¼ü´Ê£ºÃÀÍÐÂå¶û£»ËûÍ¡ÀàÒ©ÎÐļ¡¹£ËÀ»¼Õß
[abstract] objective£ºto explore the clinical effect of metoprolol + statin combined treatment for patients with myocardial infarction.Methods£º112 patients with
myocardial infarction admitted from February 2017 to February 2018 were compared and divided into a single group and a combined group according to the different medication methods£¬with 56 patients in each group.A single group was treated routinely£¬while the combined group was treated with metoprolol + statin£¬and the therapeutic effects of the single group and the combined group were observed and compared with other indicators.Results£ºthe therapeutic efficiency and clinical
indicators of the combined group were better than those of the single group£¬and P < 0.05 indicated that the difference was statistically significant.Conclusion£ºmetoprolol + statin combined therapy is effective for patients with myocardial infarction. [key words] metoprolol£»Statins£»Patients with myocardial infarction
ÐÄÔಡ×÷ΪÁÙ´²ÉϽÏΪ³£¼ûµÄÒ»ÖÖ¼²²¡£¬Í¨³£·¢ÉúÓÚÀÏÄêÈËȺµ±ÖУ¬ÁÙ´²Ñо¿ÈÏΪ£¬Ö÷ÒªÊÇÓÉÓÚ¹Ú×´±ÕÈûÒýÆð»¼Õß¾Ö²¿Ðļ¡³öÏÖ»µËÀµÄÒ»ÖÖÐÄѪ¹Üϵͳ¼²²¡£¬¸ÃÀ༲²¡Ò»µ©·¢Éú£¬½«»á¾ßÓз¢²¡¼±´Ù¡¢²¡Çé½øÕ¹¿ìËÙÒÔ¼°Ô¤ºó»Ö¸´Ð§¹û²îµÈÓÅÊÆ£¬»¼ÕßÔÚ»¼²¡ÆÚ¼ä¾ßÓÐÖ²ÐÂʸßÒÔ¼°ÖÂËÀÂʸߵÄÌصã[1]¡£Ä¿Ç°£¬ÁÙ´²É϶ÔÓÚÐļ¡¹£ËÀ»¼Õßͨ³£´ÇÈ¥ÏõËáÖ¬ÀàÒÔ¼°¿¹ÑªÐ¡°åÒ©ÎïµÈ½øÐг£¹æÖÎÁÆ£¬µ«ÊÇÖÎÁÆЧ¹û²¢²»ÀíÏë[2]¡£½ü¼¸ÄêÀ´£¬ÁÙ´²ÉÏͨ¹ýÔÚ³£¹æÖÎÁƵĻù´¡ÉÏ£¬¼ÓÓÃËûÍ¡ÀàÒ©ÎïÒÔ¼°¦ÂÊÜÌå×èÖͼÁ½øÐÐÁªºÏÖÎÁÆ£¬²»½öÄܹ»ÓÐЧ¸ÄÉÆ»¼ÕßµÄÁÙ´²Ö¢×´ºÍÌåÕ÷£¬Í¬Ê±£¬»¹Äܹ»´Ù½ø»¼ÕßµÄÔ¤ºó¿µ¸´[3]¡£±¾×éÑо¿Í¨¹ý³éÈ¡ÓÚ2017Äê2ÔÂ~2018Äê2ÔÂÊÕÖεÄ56ÀýÐļ¡¹£ËÀ»¼Õߣ¬¸øÓèÃÀÍÐÂå¶û+ËûÍ¡ÀàÒ©Îï½øÐÐÖÎÁÆ£¬ÖÎÁÆЧ¹ûÊ®·ÖÃ÷È·¡£¾ßÌåÑо¿ÈçÏ¡£
1×ÊÁÏÓë·½·¨ 1.1Ò»°ã×ÊÁÏ
±¾×éÊÔÑé¾¹ýÂ×ÀíίԱ»áµÄÐí¿É£¬ËùÓл¼ÕßÇ©ÊðÖªÇéͬÒâÊ飬³éÈ¡ÓÚ2017Äê2ÔÂ~2018Äê2ÔÂÊÕÖεÄ112ÀýÐļ¡¸ùʽ»¼Õß½øÐжԱÈÑо¿£¬¸ù¾ÝÓÃÒ©·½Ê½²»Í¬½«Æä·ÖΪµ¥Ò»×éºÍÁªºÏ×飬¸÷×é·Ö±ðΪ56Àý»¼Õߣ¬ËùÓл¼Õß¾ù×ÔÔ¸½ÓÊܱ¾×éÊÔÑé¡£ÆäÖУ¬µ¥Ò»×éÄÐÐÔ30Àý£¬Å®ÐÔ26Àý£¬×î´óÄêÁäΪ76Ë꣬×îСÄêÁäΪ38Ë꣬ƽ¾ùÄêÁ䣨58.35¡À6.28£©ËꣻÁªºÏ×éÄÐÐÔ32Àý£¬Å®ÐÔ24Àý£¬×î´óÄêÁäΪ78Ë꣬×îСÄêÁäΪ38Ë꣬ƽ¾ùÄêÁ䣨58.84¡À6.57£©Ëê¡£Á½×éÖ®¼äµÄÄêÁäºÍÐÔ±ðµÈÒ»°ã×ÊÁϾ¹ý¶Ô±Èºó£¬²îÒì²¢²»¾ßÓÐͳ¼ÆѧÒâÒ壨P©ƒ0.05£©£¬¿ÉÒԱȽϡ£ 1.2ÖÎÁÆ·½·¨
Á½×黼Õß¾ù½ÓÊÜÈëÔºÖÎÁÆ£¬²¢ÇÒ½ÓÊÜÄò³£¹æ¡¢¸ÎÉö¹¦ÄÜ¡¢Ðļ¡Ã¸Æס¢Ñª³£¹æÒÔ¼°ÐĵçͼµÈ³£¹æ¼ì²é¡£Óë´Ëͬʱ£¬»¼Õß½ÓÊÜ¿¹Äý¡¢ÎüÑõ¡¢À©¹ÚÒÔ¼°ÈÜ˨µÈ³£¹æÖÎÁÆ¡£
µ¥Ò»×é½ö²ÉÈ¡³£¹æÖÎÁƵķ½Ê½¡£µ¥Ò»×é¿Ú·þ°¢Ë¾Æ¥ÁÖ£¨Éú²ú³§¼Ò£ºÉòÑô°Â¼ªÄÈÒ©ÒµÓÐÏÞ¹«Ë¾ Åú×¼Îĺţº¹úÒ©×¼×ÖH20065051£©½øÐÐÖÎÁÆ£¬Ã¿´Î·þÓÃ0.1g£¬Ã¿Ìì·þÓÃÒ»´Î¡£Í¬Ê±£¬¿Ú·þÏõËáÒìɽÀæõ¥Æ¬£¨Éú²ú³§¼Ò£ºÉϺ£¸´µ©¸´»ªÒ©ÒµÓÐÏÞ¹«Ë¾ Åú×¼Îĺţº¹úÒ©×¼×ÖH31021370£©½øÐÐÖÎÁÆ£¬Ã¿´Î·þÓÃ10mg£¬Ã¿Ìì·þÓÃÈý´Î¡£ÔÚ´ËÆڼ䣬ÐèÒª½áºÏ»¼Õß²¡ÇéµÄ¸ÄÉÆÇé¿öÊʵ±
µ÷ÕûÓÃÒ©¼ÁÁ¿¡£30dΪһ¸öÖÎÁÆÁƳ̡£
ÁªºÏ×éÔò²ÉÈ¡ÃÀÍÐÂå¶û+ËûÍ¡ÀàÒ©ÎïµÄÁªºÏÖÎÁÆ¡£ÔÚµ¥Ò»×éµÄ»ù´¡ÉÏ£¬¼ÓÓÃÃÀÍÐÂå¶û£¨Éú²ú³§¼Ò£ºAstraZeneca AB Åú×¼Îĺţº¹úÒ©×¼×ÖJ20150044£©½øÐÐÖÎÁÆ£¬Ã¿´Î·þÓÃ12.5mg£¬Ã¿Ìì·þÓÃ2´Î£¬¸ù¾Ý»¼ÕßµÄÐÄÂÊÖ¸±êÊʵ±µ÷ÕûÓÃÒ©¼ÁÁ¿£¬Öð½¥Ôö¼Óµ½Ã¿´Î·þÓÃ50mg£¬Ã¿Ìì·þÓÃÁ½´Î¡£Óë´Ëͬʱ£¬·þÓð¢Íз¥ËûÍ¡¸Æ£¨Éú²ú³§¼Ò£ºÕ㽺£ÕýÒ©Òµ¹É·ÝÓÐÏÞ¹«Ë¾ Åú×¼Îĺţº¹úÒ©×¼×ÖH20103631£©½øÐÐÁªºÏÖÎÁÆ£¬Ã¿´Î·þÓÃ10mg£¬Ã¿Ìì·þÓÃ1´Î¡£30dΪһ¸öÖÎÁÆÁƳ̡£ 1.3ÁÙ´²¹Û²ìÖ¸±ê
¹Û²ì²¢¶Ô±Èµ¥Ò»×éºÍÁªºÏ×éµÄÖÎÁÆЧ¹ûÒÔ¼°¸÷ÏîÆäËûÖ¸±ê¡£ÁÙ´²Ö¸±êµÄ¹Û²ìÏîÄ¿°üÀ¨£ºÐÄÂÊ£¨HR£©¡¢×óÐÄ·¿ÄÚ¾¶£¨LVADD£©¡¢µ¨¹Ì´¼£¨TC£©¡¢¶þ¼â°êÊæÕÅÔçÍíÆÚ³äÓ¯Á÷Ëٱȣ¨E/A£©µÈ¡£ÖÎÁÆÓÐЧÂʵÄÆÀ¼Û±ê×¼£º¢ÙÏÔЧ¡£»¼Õß½ÓÊÜÖÎÁƺó£¬ÐØÍ´·¢×÷´ÎÊýÏà¶Ô¼õÉÙ£¬ÐŦÄܸÄÉÆ©ƒ2¼¶£¬³ÖÐø·¢×÷ʱ¼ä½µµÍ80%£¬»¼Õß½ÓÊܳ£¹æ¼ì²éºóµÄ½á¹ûÏÔʾÕý³££»¢ÚÓÐЧ¡£»¼Õß½ÓÊÜÖÎÁƺó£¬ÐØÍ´·¢×÷´ÎÊý¼õÉÙ£¬ÐŦÄܸÄÉÆ©ƒ1¼¶£¬³ÖÐø·¢×÷ʱ¼ä½µµÍ50%£¬»¼Õß½ÓÊܳ£¹æ¼ì²éºóµÄ½á¹ûÏÔʾÕý³££»¢ÛÎÞЧ¡£»¼Õß½ÓÊÜÖÎÁƺó£¬ÐØÍ´·¢×÷´ÎÊý¡¢ÐŦÄÜÒÔ¼°³ÖÐø·¢×÷ʱ¼äµÈ²¢Î´·¢ÉúÈκα仯£¬ÉõÖÁ·¢Éú¶ñ»¯¡£ÖÎÁÆÓÐЧÂÊ=£¨ÏÔЧÀýÊý+ÓÐЧÀýÊý£©/Ñо¿ÀýÊý¡Á100%¡£
1.4ͳ¼Æѧ·½·¨
±¾´ÎÑо¿ËùÉæ¼°µÄÊý¾ÝºÍÖ¸±ê£¬°üÀ¨£ºÖÎÁÆЧ¹ûºÍÁÙ´²Ö¸±êµÈ£¬¾ùÐèÒª²ÉÈ¡SPSS19.0Èí¼þ°ü½øÐÐͳ¼ÆѧµÄ·ÖÎö£¬¸÷×éÖ®¼äµÄÊý¾Ý¾¹ý¼ÆËãºóP£¼0.05±íʾ²îÒì¾ßÓÐͳ¼ÆѧÒâÒå¡£ 2½á¹û
2.1Á½×黼Õß½ÓÊÜÖÎÁƺóµÄÁÙ´²Ð§¹û±È¶Ô
ÁªºÏ×éµÄÖÎÁÆÓÐЧÂÊ53Àý£¨94.64%£©Ã÷ÏÔ¸ßÓÚµ¥Ò»×é44Àý£¨78.57%£©£¬P£¼0.05±íʾ²îÒìÓÐͳ¼ÆѧÒâÒå¡£¼û±í1£º
±í1 Á½×黼Õß½ÓÊÜÖÎÁƺóµÄÁÙ´²Ð§¹û±È¶Ô[n£¨%£©]
3ÌÖÂÛ
Ðļ¡¹£ËÀ×÷ΪÁÙ´²ÉϽÏΪ³£¼ûµÄÒ»ÖÖ¼²²¡£¬»¼ÕßÔÚ»¼²¡Æڼ佫»á±íÏÖ³ö¶ñÐÄ¡¢Å»Í¡¢ÐØÍ´ÒÔ¼°¶ñÐĵÈÁÙ´²Ö¢×´£¬ÔÚ´ËÆڼ䣬Ðļ¡¹£ËÀ»¼Õß¾ßÓв¡Çé·¢Éú¼±´Ù¡¢²¡Çé½øÕ¹¿ìËÙÒÔ¼°Ô¤ºó»Ö¸´²îµÈÌص㣬¶ÔÓÚ²¡ÇéÑÏÖصĻ¼Õ߶øÑÔ£¬ÉõÖÁ»á±íÏÖ³öÉöË¥½ßµÄÖ¢×´£¬»¼ÕßÒ»µ©³öÏÖ¶¯ÂöѪҺ¹©Ó¦¼õÉÙµÄÇé¿ö£¬½«»áÑÏÖØÓ°Ï컼ÕßµÄÉíÌ彡¿µºÍÉúÃü°²È«[4]¡£Ä¿Ç°£¬ÁÙ³öÉ϶ÔÓÚÐļ¡¹£ËÀ»¼Õ߶øÑÔ£¬ÔòÐèÒª¼°Ê±×÷³öÁÙ´²Õï¶ÏºÍÈÜ˨´¦Àí£¬Í¨³£²ÉÈ¡ÏõËáÖ¬ÀàÒ©ÎïÒÔ¼°¿¹ÑªÐ¡°åÒ©ÎïµÈ½øÐг£¹æÖÎÁÆ£¬Ëæºó½øÐÐÐļ¡ÑªÒºÔÙ¹à×¢µÄÖÎÁÆ·½·¨£¬½ø¶ø´ïµ½ÑÓ³¤»¼ÕßÉúÃü°²È«µÄÄ¿µÄ£¬´Ù½ø»¼ÕßµÄÔ¤ºó¿µ¸´¡£ÃÀÍÐÂå¶û×÷ΪһÖÖ¦Â1ÊÜÌå×èÖͼÁ£¬ÔÚʵ¼ÊÖÎÁƵĹý³ÌÖУ¬Äܹ»ÓÐЧ×è¶Ï¶ù²è·Ú°·ÀàÎïÖÊ£¬½ø¶ø´ïµ½±£»¤»¼ÕßÐÄÔ๦ÄܵÄÖÎÁÆ×÷ÓÃ[5]¡£ÓйØÑо¿ÈÏΪ£¬Ðļ¡¹£ËÀ»¼Õß´¦ÓÚ·¢²¡ÔçÆÚ£¬ÔòÐèÒª½ÓÊÜÃÀÍÐÂå¶û½øÐÐÖÎÁÆ£¬ÕâÑù²»½öÄܹ»ÓÐЧËõС»¼ÕßµÄÐļ¡¹£ËÀ·¶Î§£¬Í¬Ê±£¬»¹Äܹ»¼õÉÙÐÄÂÉʧ³£Ö¢×´µÄ·¢Éú¡£ÔÚ´Ë»ù´¡ÉϼÓÓÃËûÍ¡ÀàÒ©Îï½øÐÐÁªºÏÖÎÁÆ£¬ÔÚ¾ßÌåÓ¦ÓõĹý³ÌÖУ¬²»½öÄܹ»Îȶ¨»¼Õ߶¯ÂöÖàÑùÓ²»¯°ß¿é£¬Í¬Ê±£¬»¹Äܹ»ÓÐЧ×èÖ¹ÐÂÉú¶¯ÂöÖàÑùÓ²»¯°ß¿éµÄÐγɣ¬¶ÔÓÚ¿ØÖÆ»¼ÕßµÄÑ×ÐÔ·´Ó¦¾ßÓÐÊ®·ÖÖØÒªµÄ×÷Ó㬸üºÃÒÖÖÆ»¼ÕßѪС°åµÄ¾Û¼¯£¬½ø¶øʹµÃ»¼ÕßѪ¹ÜÄÚƤ¹¦Äܵõ½¼«´ó³Ì¶ÈµÄ¸ÄÉÆ[6]¡£Òò´Ë¿É¼û£¬ÁÙ´²É϶ÔÓÚÐļ¡¹£ËÀ»¼Õß²ÉÈ¡ÃÀÍÐÂå¶û+ËûÍ¡ÀàÒ©Îï½øÐÐÁªºÏÖÎÁƵķ½Ê½£¬Äܹ»½µµÍÐÄѪ¹ÜʼþµÄ·¢Éú¼¸ÂÊ£¬½ø¶ø¸ü¼ÓÀûÓÚ»¼ÕßµÄÔ¤ºó¿µ¸´¡£¾¹ý±¾´Î´óÁ¿µÄÊý¾Ý·ÖÎöºÍÑо¿½á¹û³ä·ÖÏÔʾ£¬ÁªºÏ×éµÄÖÎÁÆÓÐЧÂÊ53Àý£¨94.64%£©Ã÷ÏÔ¸ßÓÚµ¥Ò»×é44Àý£¨78.57%£©£¬ÁªºÏ×éÐÄÂÊ£¨HR£©¡¢×óÐÄ·¿ÄÚ¾¶£¨LVADD£©¡¢µ¨¹Ì´¼£¨TC£©¡¢¶þ¼â°êÊæÕÅÔçÍíÆÚ³äÓ¯Á÷Ëٱȣ¨E/A£©µÈÖ¸±ê¾ùÓÅÓÚµ¥Ò»×飬P£¼0.05±íʾ²îÒìÓÐͳ¼ÆѧÒâÒå¡£Òò´Ë¿É¼û£¬ÁÙ´²ÉÏͨ¹ý¶ÔÐļ¡¹£ËÀ»¼Õß²ÉÈ¡ÃÀÍÐÂå¶û+ËûÍ¡ÀàÒ©Îï½øÐÐÁªºÏÖÎÁÆ£¬²»½öÄܹ»ÔÚÒ»¶¨³Ì¶ÈÉϼõÉÙÐÄѪ¹ÜʼþµÄ·¢Éú£¬Í¬Ê±£¬»¹Äܹ»ÓÐЧ¸ÄÉÆ»¼ÕßµÄÁÙ´²ÌåÕ÷ºÍÖ¢×´£¬ÖÎÁÆЧ¹ûÈ·ÇС£ ½áÓï
×ܶøÑÔÖ®£¬Í¨¹ý¶ÔÐļ¡¹£ËÀ»¼Õß²ÉÈ¡ÃÀÍÐÂå¶û+ËûÍ¡ÀàÒ©Îï½øÐÐÁªºÏÖÎÁƵķ½Ê½£¬²»½öÄܹ»ÔÚÒ»¶¨³Ì¶ÈÉϸÄÉÆ»¼ÕßµÄÁÙ´²Ö¢×´ºÍÌåÕ÷£¬Í¬Ê±£¬»¹Äܹ»»ñÈ¡¸ü¼ÓÀíÏëµÄÖÎÁÆЧ¹û¡£ ²Î¿¼ÎÄÏ×£º
[1]²Ü¿¡½Ü.ÃÀÍÐÂå¶ûÓëËûÍ¡ÀàÒ©ÁªºÏÖÎÁÆÐļ¡¹£ËÀÁÙ´²ÁÆЧ¹Û²ì[J].ÉîÛÚÖÐÎ÷Ò½½áºÏÔÓÖ¾£¬2016£¬26£¨14£©£º159-160.
[2]Ò¦ºì.ÃÀÍÐÂå¶ûÓëËûÍ¡ÀàÒ©ÁªºÏÖÎÁÆÐļ¡¹£ËÀµÄÁÆЧ·ÖÎö[J].Öйú¼ÌÐøҽѧ½ÌÓý£¬2017£¬9£¨16£©£º168-169.
[3]ÁõÐãºì.ÃÀÍÐÂå¶ûÓëËûÍ¡ÀàÒ©ÁªºÏÖÎÁÆÐļ¡¹£ËÀµÄÁÆЧÆÀ¼Û[J].ÖйúÒ½Ò©Ö¸ÄÏ£¬2017£¬15£¨15£©£º114-114.
[4]ѦÏþ·¼.ÃÀÍÐÂå¶û£¨±¶ËûÀÖ¿Ë£©ÓëËûÍ¡ÀàÒ©ÁªºÏÖÎÁÆÐļ¡¹£ËÀ»¼ÕßµÄÁÙ´²ÁÆЧ±È½Ï[J].ÖÐÎ÷Ò½½áºÏÐÄѪ¹Ü²¡µç×ÓÔÓÖ¾£¬2017£¬5£¨25£©£º43-43.
[5]ÑîÑÞÀö£¬ÇǾê.ÃÀÍÐÂå¶ûÁªºÏËûÍ¡ÀàÒ©ÎïÖÎÁÆÐļ¡¹£ËÀµÄÁÙ´²ÁÆЧ·ÖÎö[J].ÖйúÒ½Ò©Ö¸ÄÏ£¬2017£¬15£¨12£©£º61-62.
[6]ãÆÏþÀö.Ðļ¡¹£ËÀ¸øÓèÃÀÍÐÂå¶ûÓëËûÍ¡ÀàÒ©ÁªºÏÖÎÁƵÄÁÙ´²¹Û²ì[J].ÖÐÎ÷Ò½½áºÏÐÄѪ¹Ü²¡µç×ÓÔÓÖ¾£¬2017£¬5£¨28£©£º73-73.
ÃÀÍÐÂå¶ûÓëËûÍ¡ÀàÒ©ÁªºÏÖÎÁÆÐļ¡¹£ËÀµÄÁÙ´²ÁÆЧ



